Ada Stewart, MD
Family Medicine · Columbia, SCNPI 1750333050
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (39.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Gilead at 41.8% of the total. Among family medicine clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 514 payments — averaging $362.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$78K
- Gen-probe, Inc.$73K
- Viiv Healthcare Company$23K
- Hologic Sales And Service, LLC$9K
- AstraZeneca$469
- Lilly USA, LLC$368
- plus $2K from 20 others
What the payments were for
- Consulting fees$73,62539%
- Speaking & faculty fees$72,07639%
- Travel & lodging$27,96815%
- Food & beverage$12,4207%
- Education$3070%
- Entertainment$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 203 | $77,854 |
| Gen-probe, Inc. | 16 | $72,980 |
| Viiv Healthcare Company | 150 | $23,401 |
| Hologic Sales And Service, LLC | 27 | $8,891 |
| AstraZeneca(2 entities) | 10 | $469 |
| Lilly USA, LLC | 13 | $368 |
| AbbVie | 21 | $353 |
| Novo Nordisk | 12 | $345 |
| Janssen Products, LP | 3 | $299 |
| Abbott | 10 | $294 |
| Eko Health, Inc. | 1 | $200 |
| Merck | 7 | $177 |
| Pfizer | 10 | $170 |
| Johnson & Johnson(2 entities) | 9 | $119 |
| Theratechnologies Inc. | 6 | $97 |
| Medtronic | 1 | $80 |
| Teleflex LLC | 1 | $71 |
| Dexcom, Inc. | 2 | $46 |
| Exact Sciences | 3 | $46 |
| Ultragenyx Pharmaceutical Inc. | 2 | $36 |
| Napo Pharmaceuticals Inc | 2 | $26 |
| Astellas Pharma US Inc | 1 | $25 |
| Stryker | 1 | $17 |
| Novartis | 1 | $17 |
| Evofem Biosciences, Inc. | 1 | $14 |
| Optos, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$186,410 in reported general payments places this provider in the 95th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 149 | $579,102 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 34 | $118,965 |
| DescovyEmtricitabine/Tenofov Alafenam | 47 | $102,075 |
| JulucaDolutegravir/Rilpivirine | 23 | $75,935 |
| CompleraEmtricita/Rilpivirine/Tenof Df | 15 | $57,652 |
| OzempicSemaglutide | 50 | $55,848 |
| TivicayDolutegravir Sodium | 23 | $51,238 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 11 | $43,089 |
| JanuviaSitagliptin Phosphate | 54 | $40,229 |
| JardianceEmpagliflozin | 35 | $33,695 |
| IsentressRaltegravir Potassium | 12 | $27,519 |
| MyrbetriqMirabegron | 16 | $15,290 |
| EntrestoSacubitril/Valsartan | 20 | $14,286 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $9,750 |
| EliquisApixaban | 12 | $6,715 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy, Genvoya | $77,854 | $724,266207 claims |
| Viiv Healthcare CompanyJuluca, Tivicay | $23,401 | $127,17346 claims |
| MerckJanuvia, Isentress | $177 | $67,74866 claims |
| Johnson & JohnsonComplera | $119 | $57,65215 claims |
| Novo NordiskOzempic | $345 | $55,84850 claims |
| Astellas Pharma US IncMyrbetriq | $25 | $15,29016 claims |
| NovartisEntresto | $17 | $14,28620 claims |
| PfizerEliquis | $170 | $6,71512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Columbia
- Andrew MartinColumbia$205K
- Terry NagelColumbia$112K
- Damon DanielsColumbia$15K
- John MatteiColumbia$15K
- Conigliaro JonesColumbia$14K
- Stephen BruntonWinnsboro$1.3M
- Richard WilkesMt Pleasant$216K
- Jeffrey BroderNorth Augusta$140K
- Katherine JohnsonGreenwood$80K
- Scott SmithMount Pleasant$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.